GT Biopharma, Inc. (NASDAQ:GTBP – Get Free Report) fell 13.4% during trading on Friday . The stock traded as low as $3.21 and last traded at $3.25. 10,336 shares traded hands during mid-day trading, a decline of 12% from the average session volume of 11,686 shares. The stock had previously closed at $3.75.
GT Biopharma Stock Performance
The stock has a market cap of $4.49 million, a price-to-earnings ratio of -0.36 and a beta of 0.59. The business has a 50-day simple moving average of $4.21 and a two-hundred day simple moving average of $5.95.
About GT Biopharma
GT Biopharma, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies.
Read More
- Five stocks we like better than GT Biopharma
- The Role Economic Reports Play in a Successful Investment Strategy
- 3 Stocks Leading the U.S. Agriculture Comeback
- How is Compound Interest Calculated?
- How to Use Put Debit Spreads to Profit From Falling Stocks
- Insider Buying Explained: What Investors Need to Know
- Alphabet Changes the Narrative with Its First-Ever Dividend
Receive News & Ratings for GT Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GT Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
